Literature DB >> 16061326

Relationship between sodium channel NaV1.3 expression and neuropathic pain behavior in rats.

Jill A Lindia1, Martin G Köhler, William J Martin, Catherine Abbadie.   

Abstract

A multitude of voltage-gated sodium channel subtypes (NaV1) are expressed in primary sensory neurons where they influence excitability via their role in the generation and propagation of action potentials. Peripheral nerve injury alters the expression of several NaV1subtypes, but among these only NaV1.3 is up-regulated in dorsal root ganglia (DRG) neurons. The increased expression of NaV1.3 implicates this subtype in the development and maintenance of neuropathic pain, but its contribution to neuropathic pain behavior has not been examined. Using the spared nerve injury (SNI) model, we found that peripheral nerve lesion increased NaV1.3-like immunoreactivity (-LI) in DRG neurons and that mechanical allodynia was partially alleviated following oral administration of two NaV1 blockers, mexiletine (30 and 100 mg/kg, p.o.) and lamotrigine (30 and 100 mg/kg, p.o.). Intrathecal administration of antisense oligonucleotides (4 days) selective for NaV1.3 decreased NaV1.3 immunostaining in the DRG by 50% in the SNI model, but did not attenuate mechanical or cold allodynia. Moreover, we found that only 18% of NaV1.3 positive neurons also expressed activated transcription factor-3 (ATF3), a marker of injured neurons. We then selectively axotomized a cutaneous nerve (sural) and a muscle nerve (gastrocnemius) in order to identify if NaV1.3 up-regulation is dependent on cutaneous and/or muscle afferent activation and found that the numbers of neurons expressing NaV1.3 was proportional to the magnitude of the injury, but independent of the nature of innervation. These results suggest that NaV1.3 increases in primary sensory neurons that are not directly damaged in response to injury. Thus, although NaV1.3 is up-regulated in a subpopulation of DRG neurons after injury, reduction in the expression of NaV1.3 subtype alone is not sufficient to influence the NaV1-dependent behavioral hypersensitivity associated with nerve injury.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16061326     DOI: 10.1016/j.pain.2005.05.027

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  50 in total

Review 1.  Targeting voltage-gated sodium channels for treatment for chronic visceral pain.

Authors:  Fei-Hu Qi; You-Lang Zhou; Guang-Yin Xu
Journal:  World J Gastroenterol       Date:  2011-05-21       Impact factor: 5.742

Review 2.  Na(+) channel blockers for the treatment of pain: context is everything, almost.

Authors:  Michael S Gold
Journal:  Exp Neurol       Date:  2007-12-08       Impact factor: 5.330

3.  Design and assessment of a potent sodium channel blocking derivative of mexiletine for minimizing experimental neuropathic pain in several rat models.

Authors:  Robert M Weston; Kamani R Subasinghe; Vasiliki Staikopoulos; Bevyn Jarrott
Journal:  Neurochem Res       Date:  2009-06-06       Impact factor: 3.996

Review 4.  Sodium channel blockers for the treatment of neuropathic pain.

Authors:  Anindya Bhattacharya; Alan D Wickenden; Sandra R Chaplan
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

Review 5.  Sodium channels and pain: from toxins to therapies.

Authors:  Fernanda C Cardoso; Richard J Lewis
Journal:  Br J Pharmacol       Date:  2017-09-02       Impact factor: 8.739

Review 6.  The role of sodium channels in chronic pain.

Authors:  Simon R Levinson; Songjiang Luo; Michael A Henry
Journal:  Muscle Nerve       Date:  2012-08       Impact factor: 3.217

Review 7.  Regulating excitability of peripheral afferents: emerging ion channel targets.

Authors:  Stephen G Waxman; Gerald W Zamponi
Journal:  Nat Neurosci       Date:  2014-01-28       Impact factor: 24.884

8.  Modulation of Voltage-Gated Sodium Channel Activity in Human Dorsal Root Ganglion Neurons by Herpesvirus Quiescent Infection.

Authors:  Qiaojuan Zhang; Miguel Martin-Caraballo; S Victor Hsia
Journal:  J Virol       Date:  2020-01-17       Impact factor: 5.103

9.  Intrathecal miR-96 inhibits Nav1.3 expression and alleviates neuropathic pain in rat following chronic construction injury.

Authors:  Hong-Ping Chen; Wei Zhou; Lu-Mei Kang; Han Yan; Lei Zhang; Bao-Hua Xu; Wei-Hua Cai
Journal:  Neurochem Res       Date:  2014-01       Impact factor: 3.996

10.  Increased peripheral nerve excitability and local NaV1.8 mRNA up-regulation in painful neuropathy.

Authors:  Devang Kashyap Thakor; Audrey Lin; Yoshizo Matsuka; Edward M Meyer; Supanigar Ruangsri; Ichiro Nishimura; Igor Spigelman
Journal:  Mol Pain       Date:  2009-03-25       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.